Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy.
Autoantibodies to the heat shock protein 90 (Hsp 90) have been reported as prognostic marker in breast cancer patients. Sera from 20 high-grade osteosarcoma patients were tested at the time of diagnosis by enzyme-linked immunosorbent assay. Presence of anti-Hsp90 antibodies correlated with a better response to neoadjuvant chemotherapy (P < 0.01), whereas the absence correlated with development of metastases. These data suggest that anti-Hsp90 antibodies might be of predictive value in human osteosarcoma.
Trieb
K
K
Department of Orthopedics, University of Vienna, Austria.
Gerth
R
R
Holzer
G
G
Grohs
J G
JG
Berger
P
P
Kotz
R
R
D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000097:blood*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000276:immunology*; D017024:Chemotherapy, Adjuvant; D002648:Child; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005266:Femoral Neoplasms / Q000188:drug therapy / Q000276:immunology; D018841:HSP90 Heat-Shock Proteins / Q000276:immunology*; D006801:Humans; D007085:Ilium; D008297:Male; D009363:Neoplasm Proteins / Q000276:immunology*; D012516:Osteosarcoma / Q000188:drug therapy / Q000276:immunology*; D013977:Tibia
D001323:Autoantibodies; D018841:HSP90 Heat-Shock Proteins; D009363:Neoplasm Proteins